Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 repeated-dose study of OPC-214870 in healthy volunteers
NL-OMON51813Phase 1Withdrawn
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of OPC-214870 in epilepsy and seizure disorder (4 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: CNS functional pharmacodynamic effects, OPC-214870 plasma concentrations and 2 more. Planned start Aug 2022; status: withdrawn.
02
Drugs
OPC-214870
03
Conditions
epilepsyseizure disorder
Beyond the preview
Go deeper on NL-OMON51813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51813.